Importance of dose intensity in treatment of advanced nonsmall cell lung cancer in the elderly

South Asian Journal of Cancer

Volumn 1, Issue 1, 2012, Pages 9-15

  Prasad, Narayanan ^a   Bakshi, Ashish ^a   Deshmukh, Chetan ^b   Hingmire, Sachin ^b   Ranade, A A ^c   Parikh, Purvish ^d  

^a Department of Medical Oncology   (India)

^b DEENANATH MANGESHKAR HOSPITAL   (India)

^c Clinic of General and Restorative Dentistry and Dental Implantology   (India)

^d BSES MG Hospital   (India)

Author keywords

Chemotherapy; Medical oncologist; Prolonged infusion; Response rate

Indexed keywords

CARBOPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG FATALITY; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC PATIENT; HEART DISEASE; HUMAN; HUMAN TISSUE; KIDNEY DYSFUNCTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL ONCOLOGIST; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHYSICIAN; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84871637981     PISSN: 2278330X     EISSN: 22784306     Source Type: Journal    
DOI: 10.4103/2278-330X.96494     Document Type: Article

References (18)

1. Cohen HJ. Oncology and aging. In: Hazzard WR, Blass JP, Ettinger WH, editors. Principles of Geriatric Medicine and Gerontology. 4th ed. New York: McGraw-Hill; 1998.
2. Yancik R, Ries LA. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000;14:17-23.
3. Vercelli M, Quaglia A, Casella C, Mangone L. Cancer patient survival in the elderly in Italy. Tumor 1997;83:490-6.
4. Brown JS, Eraut D, Trask C, Davison AJ. Age and treatment of lung cancer. Thorax 1996;51:564-8.
5. Non Small Cell Lung Cancer Cooperative Group. Chemotherapy in non small cell lung cancer: A meta-analysis using update data on individual patients from 52 randomized clinical Trials. Br Med J 1995;311:899-909.
6. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Under representation of patients of 65 years of age or older in cancer treatment trials. N Engl J Med 1999;341:2061-7.
7. Stinchcombe TE, Socinski MA. Drug development in patients with advanced non small cell lung cancer and poor performance status. Semin Oncol 2004;31 Suppl 11:S21-6.
8. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non small cell lung cancer: A phase II study. J Clin Oncol 1994;12:1535-40.
9. Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, et al. Activity of gemcitabine on patients with non-small cell lung cancer: A multicenter extended phase II study. Eur J Cancer 1996;32:243-8.
10. Cattel L, Airoldi M, Delprino L. Pharmacokinetic evaluation of gemcitabine and 2',2'-Difluorodeoxycytidine-5'-triphosphate after prolonged infusion in patients affected by different solid tumors. Ann Oncol 2006;17 Suppl 5:v142-7.
11. Tibaldi C, Bernardini I, Chella A. Prolonged gemcitabine infusion in advanced non-small-cell lung cancer with stable disease after gemcitabine 30-min infusion. Lung Cancer 2006;51:217-23.
12. Xu N, Shen P, Zhang XC, Yu LF, Bao HY, Shi GM, et al. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2007;59:1-7.
13. Zwitter M, Kovac V, Smrdel U, Kocijancic I, Segedin B, Vrankar M. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs 2005;16:1129-34.
14. Parikh PM, Narayanan P, Mistry RC, Agarwal JP, Pai VR, Nair R, et al. Treatment of advanced NSCLC with low dose gemcitabine and carboplatin. ASCO Abstract Book; 2005.
15. Hotta K, Ueoka H, Kiura K, Tabata M, Tanimoto M. An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2004;46:61-76.
16. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, et al. A prognostic model for advanced stage nonsmall cell lung cancer: Pooled analysis of North Central Cancer Treatment Group trials. Cancer 2006;107:781-92.
17. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32.
18. Hespanhol V, Queiroga H, Magalhaes A. Survival predictors in advanced non-small cell lung cancer. Lung Cancer 1995;13:253-67.